What makes you think it is too cheap.
First half results show proforma underlying NPAT of $1.27 m
That includes a full 6 month contribution from Analytica and excludes one-off costs.
If they achieve full year NPAT of $2.6m, that puts them on a PE of 38 with a share price of 20c.
Seems to be pricing in lots of future growth already on that basis.
